Pharmala Biotech (MDMA) Q3 2026 earnings summary

Executive summary

• Achieved significant revenue growth and improved financial position compared to 2025, driven by strong sales and strategic transactions.

• Executed a notable transaction with Jupiter Neuroscience, announced in Q3 and completed in Q4.

Financial highlights

• Revenue for the nine months ended May 31, 2026 reached over $1,000,000, up from $338,000 year-over-year; Q3 revenue was $513,000 versus $135,000 in Q3 2025.

• Net loss for Q3 2026 was $499,759, and for the nine months was $1,247,150, both improved from $524,235 and $1,814,110 in the prior year periods.

• Cash used in operating activities for the nine months was $673,588, down from $748,758 year-over-year.

Outlook and guidance

• Licensing agreements are expected to provide further revenue opportunities and reflect the potential value of ongoing R&D.